StockDuty ← Dashboard Sep 17, 2026 01:22 PM ET
CatalystFDA/Bio

AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting

AbbVie presents Phase 3 Etentamig results and multiple myeloma data at 2026 IMS Meeting.

What changed
AbbVie presents Phase 3 Etentamig results and multiple myeloma data at 2026 IMS Meeting.
Why it matters
AbbVie presents Phase 3 Etentamig results and multiple myeloma data at 2026 IMS Meeting. — impact context not separately stored; see What changed.
Sources
eodhd
Related signals
PHASE 1 OF INDIA - US TRADE PACT HINGES ON SECTION 301 PROBE , OFFICIAL SAYS →PITNEY BOWES OUTLINES PHASE 2 STRATEGIC REVIEW WHILE PUSHING NEAREST DEBT MATURITY TO MARCH 2029 - SEEKINGALPHA →UNICYCIVE PLUMMETS FOLLOWING SECOND CRL FOR OLC FOR HYPERPHOSPHATEMIA - SEEKINGALPHA →